Semaglutide Investigated for Neuroprotective, Anti-inflammatory Properties in Parkinson's Disease
Background
Parkinson's disease (PD) is a debilitating, progressive neurodegenerative disorder for which no disease-modifying treatments are currently approved. Existing therapies primarily manage symptoms without addressing the underlying pathology or slowing disease progression. This significant unmet medical need drives research into novel therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes, have garnered attention due to their demonstrated neuroprotective and anti-inflammatory effects in various preclinical models of neurodegeneration. This suggests a compelling rationale for investigating their potential therapeutic role in PD, targeting pathways implicated in neuronal survival and inflammation.